The CRISPR patent landscape kept on developing since February with more than 100 new patent publications in the past two months. We have now searched, reviewed and categorized 1340 patent families in our latest CRISPR patent analytics data set. Continue reading
The CRISPR patent landscape keeps on developing with now an average of two new patent publications every day. We have now searched, reviewed and categorized 1198 patent families in our February 2016 CRISPR patent analytics data set. The recent conclusions by the USPTO on the CRISPR pioneering patent interference has received significant media attention and finally confirmed the diversity of the CRISPR licensing landscape. We have provided our 2017 key findings to a number of analysts in the field, and are working hard to keep on extracting and sorting meaningful CRISPR patent coverage information for our customers on a monthly basis.
The CRISPR patent landscape keeps on developing at an increasing pace in 2017, with now up to three new patent families published every day! We have searched, reviewed and categorized more than 1146 patent families, now surveyed in our just released 2017 CRISPR patent landscape report.
The past 24 hours have brought new light and significant moves in the complex CRISPR patent landscape.
First (that was in European time zone!), our CRISPR expert Fabien Palazzoli celebrated the 1000th CRISPR patent family extraction out of the worldwide published patent databases. Our next monthly update will actually feature more than 1050 classified and categorized CRISPR patent families – more than 10 times the initial set of our first landscape release back in summer 2014!
Corinne Le Buhan will be teaching IP management “From IP strategy to IP operations” at next IEEPI session in Paris this Friday, November 25. This professional training will help you learn about practical IP strategies and key IP management challenges from various business environments, how to define your own organisation IP strategy and how to implement it in practice with various IP development, enforcement and commercialisation tactics.
In this one-day session, emphasis is put on practical management tools and checklists, illustrated with case studies from various industries, and a situational workshop experimentation.
A couple of seats are available as last minute registration – don’t miss yours!
The CRISPR patent landscape keeps on developing with in average a new patent publication every day. We have now searched, reviewed and categorized more than 920 patent families in our October 2016 CRISPR patent analytics data set.
The CRISPR patent landscape keeps on developing with in average a new patent publication every day. We have now searched, reviewed and categorized more than 850 patent families in our CRISPR patent analytics database.
Earlier this month, we were interviewed by The Scientist regarding the side inventorship dispute between Feng Zhang and Luciano Marraffini on some of the Broad patent applications. Public registers at the USPTO, WIPO and the EPO expose further details of the otherwise un-publicized legal battles for invention ownership between their employers (the Broad Institute of Harvard and MIT and Rockfeller University), back from the 2012-2013 early filings.
From January to July 2016, our CRISPR patent monitoring set has almost doubled, from 489 to 787 published patent families. We now search, review and classify them on a monthly basis to stay up to date, watching for the latest technology coverage and application developments as can be derived from the individual patent claims.
The CRISPR technology has a wide range of target applications, from agronomy to medicine. As we celebrate the 2nd birthday of CRISPR patent analytics services at IPStudies and the 4th year of the CRISPR-Cas9 invention, a few application areas show an increasing competitive activity in the landscape. On CAR-T (chimeric antigen receptor T) cell immunotherapy, we now find more than twenty patent applications in the CRISPR landscape. As could be expected from their marketing/communication, a number of pharmaceutical players and CRISPR technology development pioneers have actively positioned their IP in that domain, namely: